Skip to content

Drug Target Review Features the Science Behind GATC’s New Addiction Drug Candidate

July 23, 2026 —  A new feature in Drug Target Review explores the science and data behind GATC Health’s discovery of a potential new treatment for opioid use disorder.

Authored by GATC Health Co-founder and Chief Technology Officer Jayson Uffens, the article, titled “How AI and human biology data led to a new addiction drug candidate,” details how the integration of human biology data and advanced AI drastically improves drug target selection.

Read the full article at Drug Target Review here: How AI and human biology data led to a new addiction drug candidate